Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website

BioCryst Pharmaceuticals reported $85.61M in Gross Profit on Sales for its fiscal quarter ending in September of 2023.

Gross Profit On Sales Change Date
Alnylam Pharmaceuticals USD 666.22M 432.84M Sep/2023
BioCryst Pharmaceuticals USD 85.61M 4.06M Sep/2023
Chugai Pharma JPY 179.64B 3.89B Sep/2023
Daiichi Sankyo JPY 280.77B 23.61B Sep/2023
Gilead Sciences USD 5.49B 329M Sep/2023
GlaxoSmithKline GBP 5.91B 626M Sep/2023
Incyte USD 864.63M 27.35M Sep/2023
Intra Cellular Therapies USD 117.04M 13.42M Sep/2023
Ionis Pharmaceuticals USD 142.02M 43.86M Sep/2023
Neurocrine Biosciences USD 487.6M 46.4M Sep/2023
Novavax USD 88.06M 281.09M Sep/2023
PTC Therapeutics USD 187.08M 13.99M Sep/2023
Regeneron Pharmaceuticals USD 2.93B 173.1M Sep/2023
Roche Holding CHF 22.16B 123M Jun/2023
Sarepta Therapeutics USD 294.79M 67.68M Sep/2023
Ultragenyx Pharmaceutical USD 87.06M 11.33M Sep/2023
Vertex Pharmaceuticals USD 2.16B 19.8M Sep/2023